PALISADE BIO INC
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
PALI$1.13-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
(Unaudited)
| Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares* · Amount* | |||||||
| Balance, December 31, 2023 | 200,000 | $2 | 618,056 | $6 | $132,811 | $(121,506) | $11,313 |
| Net loss | — | — | — | — | — | (3,527) | (3,527) |
| Stock-based compensation expense and related charges | — | — | — | — | 118 | — | 118 |
| Issuance of common stock for vesting of restricted stock units | — | — | 5,186 | — | — | — | — |
| Issuance of common stock in connection with warrant inducement, net of issuance costs of $2,412 (Note 5) | — | — | 228,162 | 2 | 2,158 | — | 2,160 |
| Reverse stock split fractional share settlement | — | — | (102) | — | — | — | — |
| Balance, March 31, 2024 | 200,000 | $2 | 851,302 | $8 | $135,087 | $(125,033) | $10,064 |
| Preferred Stock · Common Stock · AdditionalPaid-inCapital* · AccumulatedDeficit · TotalStockholders'Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares* · Amount* | |||||||
| Balance, December 31, 2022 | 200,000 | $2 | 196,287 | $2 | $121,665 | $(109,190) | $12,479 |
| Net loss | — | — | — | — | — | (2,340) | (2,340) |
| Stock-based compensation expense and related charges | — | — | — | — | 93 | — | 93 |
| Issuance of common stock in connection with exercise of warrants | — | — | 76,188 | 1 | 1,348 | — | 1,349 |
| Issuance of common stock and warrants in January 2023 Offering, net of issuance costs of $507 | — | — | 31,789 | — | 2,166 | — | 2,166 |
| Balance, March 31, 2023 | 200,000 | $2 | 304,264 | $3 | $125,272 | $(111,530) | $13,747 |
(*) Adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.
Condensed Consolidated Stateme
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.